Statera Biopharma (NASDAQ:STAB) stock is rising higher on Thursday as the company holds a meeting with The Nasdaq Stock Market’s Nasdaq Hearings Panel. The meeting with the Nasdaq Hearings Panel has to do with a delisting notice the company received for STAB shares. The problem that has it facing delisting is a delay on the release of earnings reports. Just how many earnings reports has Statera Biopharma failed to file? The company still hasn’t filed 2021 earnings or earnings reports for the first and second quarters of 2022. As a result, it doesn’t meet the filing requirements to remain on the exchange.
Very early this morning, Shell (NYSE:SHEL) released a third-quarter 2022 “update note.” There were plenty of numbers, but not much commentary. However, a Wall Street Journal article effectively filled in the blanks. It articulated what many traders were probably thinking: A volatile natural gas market is likely to cause problems for Shell. Consequently, SHEL stock sank quickly today.
Camber Energy (NYSEAMERICAN:CEI), a carbon capture company with a spotty track record, is drawing investors’ interest again after CEI stock regained compliance with listing standards and renewed interest in oil and gas stocks. CEI stock was up 7% in early trading on Oct. 6, with a price of about 25 cents/share but has since dropped down to the red during morning trading. The market capitalization was $117 million.
